Physician profile
Mark D Avart
NPI 1942208285
$1,297.17
in general payments reported to CMS, 2019-2025
15 companies · $44.80 in 2025
The $44.80 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $111 · 2021: $193 · 2022: $12.83 · 2023: $245 · 2024: $206 · 2025: $44.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $267.27 | 2023-2024 | Gel-One Cross-Linked Hyaluronate |
| Electronic Waveform Lab, INC. | $200.93 | 2021-2023 | |
| Bioventus LLC | $161.41 | 2019-2024 | Durolane, Durolane |
| Stryker Corporation | $147.49 | 2019 | |
| Si-Bone, INC. | $144.07 | 2019 | |
| Depuy Synthes Sales INC. | $116.35 | 2019-2025 | Orthovisc |
| Medtronic, INC. | $50.11 | 2023 | Biosyn |
| Boston Scientific Corporation | $49.89 | 2024 | Watchman Flx |
| Ermi LLC | $35.72 | 2019-2020 | |
| Assertio Therapeutics, INC. | $34.42 | 2019 | |
| Aytu Biopharma, INC. | $26.87 | 2019 | |
| Fidia Pharma USA INC. | $18.39 | 2025 | Hymovis |
| Kci USA, INC. | $16.06 | 2021 | |
| Convatec INC. | $15.36 | 2019 | |
| Horizon Therapeutics Plc | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Avart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.